Galactophore Department, The Second Clinical Medical College, Yangtze University, Jingzhou Central Hospital, Jingzhou, China.
Pharmacy Department, Jingzhou Central Hospital, Jingzhou, China.
J Cell Biochem. 2018 Sep;119(9):7577-7584. doi: 10.1002/jcb.27087. Epub 2018 Jun 12.
The clinical prognosis of breast cancer (BC) patients remains poor. Studies on BC microarrays GSE37751, GSE7390, and GSE21653 were reanalyzed to characterize the expressions of annexin A7 (ANXA7) in BC patients and the corresponding normal breast tissues and the correlation between ANXA7 expression and clinical characteristics and survivals of BC patients. Gene set enrichment analysis (GSEA) was applied to investigate the exact mechanisms as for the expression of ANXA7 and the proliferation of BC cells. The level of ANXA7 expression was significantly decreased in BC patients than that in normal controls (P < .0001). BC patients in the ANXA7 high-expression group were associated with better clinical features such as tumor size; histopathological grading; estrogen receptors; and clinical risk groups according to St Gallen criteria, Nottingham prognostic index criteria, and Veridex signature compared with those in the ANXA7 low-expression group. Higher expression of ANXA7 predicted better prognosis of BC patients. The result of GSEA indicated that ANXA7 might inhibit the proliferation of BC cells through biological processes involved in androgen response, heme metabolism, and oxidative phosphorylation. The messenger RNA and protein levels of ANXA7 were decreased in BC tissues compared with those in normal breast tissues. Our results proved that ANXA7 was downregulated in BC cells and that a higher expression of ANXA7 was associated with better prognosis of BC patients.
乳腺癌 (BC) 患者的临床预后仍然较差。重新分析了 BC 微阵列 GSE37751、GSE7390 和 GSE21653 的研究，以描述 ANXA7 在 BC 患者和相应的正常乳腺组织中的表达，以及 ANXA7 表达与 BC 患者临床特征和生存的相关性。应用基因集富集分析 (GSEA) 研究 ANXA7 表达和 BC 细胞增殖的确切机制。与正常对照组相比，BC 患者的 ANXA7 表达水平显著降低 (P <.0001)。与 ANXA7 低表达组相比，ANXA7 高表达组的 BC 患者具有更好的临床特征，如肿瘤大小；组织病理学分级；雌激素受体；以及根据圣加仑标准、诺丁汉预后指数标准和 Veridex 特征的临床风险组。较高的 ANXA7 表达预示着 BC 患者更好的预后。GSEA 的结果表明，ANXA7 可能通过涉及雄激素反应、血红素代谢和氧化磷酸化的生物学过程抑制 BC 细胞的增殖。与正常乳腺组织相比，BC 组织中 ANXA7 的信使 RNA 和蛋白水平降低。我们的结果证明 ANXA7 在 BC 细胞中下调，并且 ANXA7 的高表达与 BC 患者的较好预后相关。
